ViiV's Data Blitz: Reshaping HIV Treatment and Prevention Standards

RIO DE JANEIRO, BRAZIL – July 21, 2026 – As the global health community prepares to convene for the 26th International AIDS Conference, ViiV Healthcare is poised to execute a strategic data blitz designed to reshape the standards of HIV care. The GSK-majority-owned company will present over 20 abstracts detailing a multi-pronged offensive that reinforces its leadership in long-acting therapies and mounts a direct challenge to established treatment protocols. This isn't merely a data dump; it's a carefully orchestrated campaign providing actionable intelligence on the future of HIV management, where patient burden is minimized and treatment efficacy is maximized.

From a head-to-head showdown between leading oral regimens to groundbreaking real-world evidence for injectable treatments in the most challenging settings, ViiV's presentations signal a paradigm shift. The underlying strategy is clear: leverage its expertise in integrase strand transfer inhibitors (INSTIs)—the gold-standard class of drugs that prevent HIV from integrating into human DNA—to create simpler, less frequent, and more accessible options for both treatment and prevention.

The Battle for First-Line Treatment: Two Drugs vs. Three

A central pillar of ViiV’s presentation is the primary endpoint data from the VOGUE study. In a highly anticipated showdown, this Phase IIIb trial directly compares the company's two-drug regimen, Dovato (dolutegravir/lamivudine), against the market-leading three-drug regimen, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), from competitor Gilead Sciences. For years, the prevailing wisdom has favored three-drug cocktails to suppress the virus and prevent resistance. ViiV has been methodically working to dismantle this dogma, arguing that a powerful two-drug combination can be just as effective while reducing a patient's long-term drug exposure—a critical factor in managing a chronic condition over a lifetime.

The hidden cost of progress in HIV has always been the cumulative toxicity and side effects of lifelong medication. If the VOGUE data demonstrates that Dovato is non-inferior to Biktarvy, particularly in treatment-naïve adults and even those with high viral loads, it could fundamentally alter first-line treatment guidelines. This would provide clinicians with robust evidence to de-escalate therapy without compromising virologic control, a significant win for patient health and a major competitive coup for ViiV in the lucrative daily oral market. A pooled analysis being presented alongside VOGUE will further scrutinize on-study viral events, aiming to build an unassailable case for the two-drug approach.

The Injection Revolution Gains Real-World Momentum

Beyond the daily pill, ViiV is doubling down on its pioneering work in long-acting injectable (LAI) therapies. While the concept of replacing 365 daily pills with six or twelve injections a year is compelling, the critical test is its performance outside the pristine conditions of a clinical trial. The data emerging from AIDS 2026 provides a resounding answer.

Late-breaking 96-week results from the LATA study are particularly significant. This trial evaluates the injectable treatment Cabenuva (cabotegravir + rilpivirine LA) against a daily oral standard of care in adolescents living with HIV across sub-Saharan Africa. Success in this population and setting is a crucial proof point for global health equity, demonstrating that LAIs are not just a luxury for well-resourced health systems but a viable, and potentially superior, option for young people who face unique adherence challenges. Similarly, 96-week results from the IMPALA study will offer insights into the use of Cabenuva in African adults with prior adherence difficulties, directly addressing one of the most persistent problems in HIV care.

In the US, real-world data from the large OPERA cohort will compare Cabenuva’s effectiveness directly against daily oral Biktarvy. This evidence is essential for payers and providers who need to see how these innovative but logistically more complex therapies perform in routine clinical practice. By demonstrating comparable or superior virologic suppression in the real world, ViiV aims to accelerate the transition from daily pills to long-acting injections as a mainstream standard of care.

Redefining Prevention: The Push for Less Frequent Dosing

Perhaps the most forward-looking aspect of ViiV's presentation lies in the realm of pre-exposure prophylaxis (PrEP). The company's injectable PrEP, Apretude (cabotegravir LA), has already transformed the prevention landscape by offering an alternative to daily pills. Now, ViiV is pushing the boundaries even further. The EXTEND 4M trial will introduce a new formulation of cabotegravir designed to be administered just three times a year. A quarterly injection for HIV prevention would be a monumental public health achievement, drastically lowering the adherence barrier that currently limits the real-world effectiveness of PrEP.

This move also sharpens the competitive dynamics. The CLARITY study will present participant-reported outcomes comparing experiences with Apretude versus lenacapavir, Gilead’s long-acting PrEP candidate. While clinical efficacy is paramount, patient experience—including injection site reactions and overall convenience—will be a key differentiator in a competitive market. Furthermore, real-world data from the CAPTIVATE and PrEPFACTS studies will illuminate how Apretude is being used in routine US clinical practice, providing critical intelligence on uptake, adherence patterns, and operational challenges that can inform broader implementation strategies.

Beyond the Syringe: The Patient Voice in Treatment Choice

Rounding out its comprehensive data set, ViiV is presenting findings from the 'Ask Us Europe' survey. This community-led initiative explores a crucial, often overlooked, aspect of care: the quality of conversations between people living with HIV and their healthcare providers about treatment options. The data will shed light on whether discussions about long-acting therapies are happening equitably, especially for marginalized groups like trans, non-binary, and gender-diverse individuals who may have complex support needs.

This focus on patient-provider communication provides a vital qualitative layer to the clinical data. It underscores that the availability of innovative medicine is only half the battle; ensuring patients are empowered to make informed choices that fit their lives is equally important. For professionals seeking a long-term view of the market, this data is a reminder that patient preference and shared decision-making are becoming powerful drivers of therapeutic adoption, and companies that ignore the patient voice do so at their peril.